You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 91 - 100 of 207728 results
  1. OPERA: Optimizing a potassium-ion electrolyte for revolutionary automotive batteries

    SBC: Project K Energy, Inc.            Topic: 1

    We propose to develop and commercialize a potassium-ion battery for use in electric vehicles (EVs). The fundamental properties of potassium transport in organic electrolytes allow for fast charging from 0 to 80% capacity in less than 5 minutes. The battery will pair a stable, open-framework cathode based on a Prussian blue analog (PBA) with a conventional graphite anode for a high-performance batt ...

    SBIR Phase II 2023 Department of EnergyARPA-E
  2. OPERA: Optimizing a potassium-ion electrolyte for revolutionary automotive batteries

    SBC: Project K Energy, Inc.            Topic: 1

    We propose to develop and commercialize a potassium-ion battery for use in electric vehicles (EVs). The fundamental properties of potassium transport in organic electrolytes allow for fast charging from 0 to 80% capacity in less than 5 minutes. The battery will pair a stable, open-framework cathode based on a Prussian blue analog (PBA) with a conventional graphite anode for a high-performance batt ...

    SBIR Phase II 2023 Department of EnergyARPA-E
  3. Mapping Risks and Stress Testing Resilience in Critical Mineral Supply Chains

    SBC: RESILIENCE ANALYTICS LLC            Topic: C5613b

    The sheer size, complexity, and resource requirements within critical mineral supply chains leave them vulnerable to disruption or exploitation, affecting critical national infrastructure and economic security. Various unpredictable political, environmental, infrastructural, or climactic stressors can have systemic and cascading disruption upon everything from basic commodities to critical mineral ...

    SBIR Phase I 2023 Department of Energy
  4. P22-145 ITM Ph II Expansion (CCHAT Protocol)

    SBC: SOAR TECHNOLOGY INC            Topic: DHA17B002

    Current artificial intelligence (AI) algorithms are built to align with ground truth or consensus of trusted human decision-makers. This is not effective for difficult decision domains, such as patient triage, where even experts disagree on the best course of action. A key reason human experts disagree is that their individual attributes influence their decision-making. To develop human-off-the-lo ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  5. Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza

    SBC: TFF PHARMACEUTICALS, INC.            Topic: NIAID

    PROJECT SUMMARY TFF Pharmaceuticals (TFFP) is developing a shelf-stable thin-film freeze (TFF) dry powder universal flu vaccine. Commercialization of this product would provide the first vaccine that is at least 75% effective against symptomatic influenza virus infection, with the added benefit of easy delivery and storage at room temperature to facilitate broad, cost-effective distribution. With ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic UV Disinfection System to Prevent Catheter Related Bloodstream Infections (CRBSIs) in Patients with Peripherally Inserted Central Catheters (PICCs)

    SBC: PURACATH MEDICAL INC            Topic: NIAID

    Abstract The goal of PuraCath’s Commercial Readiness Pilot is to prepare for commercialization of a therapeutic system for disinfection of a needleless connector for Peripherally Inserted Central Catheters that reduces the risk of intraluminal colonization as a source of catheter-related bloodstream infections. The system uses ultraviolet light to eliminate microbes and biofilm derived from fung ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    In this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Commercializing CivaSheet for Pancreatic Cancer Patients

    SBC: CIVATECH ONCOLOGY INC            Topic: NCI

    CivaTech Oncology’s mission is to provide improved radiation therapy directly to diseased tissues while sparing healthy tissues. With NIH/NCI SBIR support, the Company has eliminated local recurrence of disease in pancreatic cancer patients – a huge success. Pancreatic cancer is predicted to soon become the most commonly diagnosed cancer in the US and there are no significant, impactful therap ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens

    SBC: Curza Inc            Topic: NIAID

    Project Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier

    SBC: IllExcor Therapeutics LLC            Topic: NHLBI

    Acute respiratory distress syndrome (ARDS) is a life-threatening condition featuring acute onset of non- cardiogenic respiratory failure and hypoxemia. Consequently, patients with ARDS have severe hypoxemia due to a significant impairment of gas exchange, and the goal of supportive therapy is to prevent critical tissue hypoxia, which can cause acute cardiac arrest and death or have long-term neuro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government